In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ID Biomedical Corp.

Division of GlaxoSmithKline PLC
www.idbiomedical.com

Latest From ID Biomedical Corp.

Product Approvals In Brief: Xalkori Gets Full Approval, H5N1 Flu Vaccine Approved

Pfizer gains full approval for its lung cancer treatment Xalkori, following accelerated approval in 2011; also updates on ID Biomedical’s adjuvanted H5N1 flu vaccine; a new indication for Bayer/Onyx’s cancer treatment Nexavar; a new formulation for Merck’s antifungal Noxafil; and BTG’s new varicose vein product Varithena.

BioPharmaceutical United States

GSK’s Quad Flu Vaccine Clears FDA; B-Strain Protection Gap Could Drive Adoption

About one-third of the influenza B viruses tested this year are from the strain not included in this season’s trivalent vaccine; GlaxoSmithKline’s Fluarix is the second approved seasonal flu vaccine to protect against four virus strains, and by next season half of the U.S. manufacturers could be offering a broader spectrum product.

BioPharmaceutical United States

Flu Vaccine Production Down Slightly This Season; Strains Get Overhaul

FDA encourages people to get vaccinations since two of the three virus strains in this season’s flu vaccines differ from last season’s; several manufacturers plan to distribute slightly fewer doses in 2012-2013 than in the prior year.

BioPharmaceutical United States

Solid Support for Flu Vaccine Development

Vaccines generally are one of the few areas in pharmaceutical development where government incentives, science, and intellectual property are in alignment to favor commercialization. This is particularly true for flu vaccine, where recent events have drawn the attention of government and Big Pharma. That, plus the advent of new adjuvant technology and innovative manufacturing methods, signals opportunity for new players.
BioPharmaceutical Manufacturing
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Anthony F Holler, MD, CEO
    Kevin A Carlson, VP, Fin. & Admin. & CFO
    John Trizzino, SVP, Bus. Dev.
    George Lowell, CSO
    David Burt, VP, Research
  • Contact Info
  • ID Biomedical Corp.
    Phone: (604) 431-9314
    1510-800 West Pender St.
    Vancouver, V6C 2V6
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register